The burden of cardiovascular disease in prostate cancer: prevalence, pathophysiology, and implications for integrated

Ikponmwosa Jude Ogieuhi1, Chidera Stanley Anthony2, Victor Oluwatomiwa Ajekiigbe3

  • 1Northwestern Medicine McHenry Hospital, McHenry, IL, USA. Jude.ogieuhi@gmail.com.

Insights

Cardiovascular disease (CVD) and prostate cancer (PCa) share risk factors and treatment side effects. Integrated approaches, including lifestyle changes and monitoring, can improve outcomes for patients with both conditions.

Area of Science:

  • Oncology
  • Cardiology
  • Integrative Medicine

Background:

  • Cardiovascular disease (CVD) and cancer, particularly prostate cancer (PCa), are leading global health issues.
  • Shared risk factors include metabolic disorders, inflammation, and hormonal abnormalities.
  • PCa treatments like androgen deprivation therapy (ADT) can exacerbate cardiovascular conditions.

Purpose of the Study:

  • To examine the relationship between CVD and PCa.
  • To understand pathophysiological links and the impact of comorbidity on patient outcomes.
  • To identify gaps in current clinical guidelines and research needs.

Main Methods:

  • Review of existing literature on CVD and PCa comorbidity.
  • Analysis of cardiovascular side effects of PCa treatments (ADT, ARSI).
  • Evaluation of integrated management strategies and technological interventions.

Main Results:

  • PCa treatments are associated with increased risks of hypertension, myocardial infarction, and metabolic issues.
  • Lifestyle modifications, exercise, statins, and antihypertensives show potential in mitigating cardiovascular risks.
  • Wearable devices and telemedicine offer real-time monitoring for improved patient outcomes.

Conclusions:

  • There are significant gaps in cardio-oncology integration within clinical guidelines.
  • Further research into biomarkers, inflammatory pathways, and personalized therapies is crucial.
  • Integrated care approaches are essential for improving quality of life and survival in patients with comorbid CVD and PCa.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...